« December 2004 | Main | February 2005 »

January 31, 2022

Could The Essence of Hot Peppers Boost Natural Weight Loss

Former sinus and headache sufferers appear to be experiencing a strange side effect from the world’s first hot pepper nasal spray. Apparently this “positive” reaction amounts to a reduced appetite that could one day provide a natural answer to weight control.

Albany, NY (PRWEB) January 31, 2022 -- Many sinus and headache sufferers appear to be experiencing a strange side effect from the world’s first hot pepper nasal spray. Apparently this “positive” side effect amounts to a reduced appetite and possibly increased metabolic activity.

Within the past year, Sinus Buster all natural hot pepper nasal spray has become a phenomenon in the lucrative “Sinus & Headache” market. When it was first introduced via the internet in early 2004, Sinus Buster was viewed as a joke of sorts, but within only a few months, this spicy supplement became the most talked about remedy among physicians and their patients suffering from a variety of chronic sinus, headache and allergy conditions.

Yet as word of the miraculous properties of Sinus Buster nasal spray spread across the world, nobody ever imagined this incredible formula would also prove to be a potential remedy for obesity. Yes – believe it or not, this seemingly miraculous substance may also prove to be an important tool for appetite control which could obviously lead toweight loss and weight control.

The main active ingredient in Sinus Buster is Capsaicin, a natural compound found in hot peppers of the Capsicum family. This family includes mild peppers such as “Paprika,” all the way up to the notoriously hot “Habaneras”.

Capsaicin has been used for medicinal purposes for centuries, and today’s medical experts recommend this natural substance for a variety of medical conditions. Cardiologists regularly recommend a diet supplemented with hot peppers to aid in the prevention of heart disease, stroke and other circulatory related conditions.

It’s well regarded by many researchers that capsaicin increases the metabolic activity in humans and animals, but to what extent researchers still are not certain. Nonetheless the clinical facts are real. Several controlled studies have shown conclusively that capsaicin increases circulatory activity while also suppressing the appetite. As far as most researchers are concerned, the effects of capsaicin are both “expected and surprising” in the same breath. For instance, recent studies have shown that a meal containing high levels of capsaicin can reduce the average calorie intake by more than 200 calories per day.

SiCap Industries, the exclusive makers of Sinus Buster capsaicin nasal spray are equally surprised by the supposed weight controlling possibilities of capsaicin in their unique formula. According to SiCap officials, they never dreamed their formula would also aide in weight loss, but as more and more customers began to report the side effect of appetite suppression, SiCap’s Research and Development team has begun to take those reports seriously.

In response to the inspiring anecdotal evidence, the company has been concentrating on the development of a super efficient capsaicin based formula designed specifically to boost the metabolism while suppressing the appetite.

“When Sinus Buster was first launched in 2004 we never dreamed it would become so many things to so many people. First it was the way it stops headaches which we already knew about, but then it became clear that Buster could also relieve many chronic sinus conditions and allergies, but now we’re hearing about appetite control. As crazy as it sounds, there is definite scientific evidence showing capsaicin suppresses the appetite. In fact since we first started hearing this from customers, I started using it all the time and I’ll tell you what….it seems to work. Who knows though, maybe it’s a placebo effect due to the testimonials from our customers,” admits Wayne Perry, inventor of the Sinus Buster formula and president of SiCap Industries.

Interestingly enough, the exact effect of Perry’s formula is about to be tested in a Class 1 clinical trial that will be conducted through a major European research institute. Although Perry is hesitant to disclose the exact details, he does admit the deal is nearly complete, and if the results prove to be what the proposed researchers believe, Sinus Buster may find a whole new market – “Weight Loss”.

“There’s no doubt we’re excited about the possibility of a clincal trial, but we are also taking the whole thing with a grain of salt. Besides we already sell a weight loss supplement “Pepper Boost” which is a metabolic stimulator and an appetite suppressant. We have a lot of customers who’ve definitely benefited from Pepper Boost, but Sinus Buster was not designed to aid in weight control,” says Perry.

SiCap is also close to releasing the world’s first tinctured herbal infusion made with natural mushrooms and peppers. Originally, the company planned on marketing this new extract as an additive in their original Pepper Boost formula. Then after tedious experimentation, SiCap’s “Research & Development” team surprised their corporate superiors by recommending this new extract be used as an exclusive product.

“When I came into that meeting, the board members expected a dissertation about the new and improved Pepper Boost formula using our new extract. We shocked the hell out of them by recommending this new extract as an exclusive new formula to be marketed on its’ own. Three drops of this stuff in a 16 ounce bottle of water is equivalent to an entire two ounce bottle of Pepper Boost and it also contains the immune boosting properties of polysaccharides found in medicinal mushrooms. The properties of this new extract changed the plans of our company almost overnight. We had planned on unveiling the new Pepper Boost formula sometime this month. We even had the new labels ready because we were planning to offer this new formula in 32 ounce bottles so people could drink several ounces a day, but once we started working with our own peppershroom extract, we realized this additive was powerful enough to stand on its' own," says Perry.

SiCap's "Peppershroom" tincture is made with four varieties of mushrooms and three varieties of hot peppers. In addition, SiCap adds an organic Green Tea extract, Cinnamon Bark oil and Peppermint extract to the mix for an intoxicating aroma and flavor. According to the company, they recommend adding only (3-5) drops to 16 ounces of water or juice at least three times daily prior to eating.

Although SiCap's management team believes clinical trials using their Sinus Buster formula to combat obesity may prove positive, they also claim the true answer will be found through the oral ingestion of Capsaicin.

“Sinus Buster was designed to fight chronic headaches, sinus and allergy conditions, but we never dreamed it could also help with an overactive appetite, but I do believe although it does seem to help many people, the true answer to controlling the appetite will come from oral ingestion, but we're also not sure what the effects of our peppershroom extract may have when taken intranasally. In fact we may even add our peppershroom extract to a new maximum strength Sinus Buster formula....down the road that is. Uhh Ohh, I’m giving away company secrets again,” boasts Perry with a sly grin.

Perry’s new mushroom pepper extract is truly as powerful as its’ inventor lets on. I placed three drops in a 20 ounce bottle of water and the results were astounding. As I shook the bottle, the water appeared to bubble and boil like nothing I’d ever seen. Then as I removed the top and sniffed the mixture, the immediate discharge cleared my sinuses instantly. As the bubbling water cleared, I hesitantly drank a third of the bottle in one long gulp. There was a sudden rush and a slight burn around my lips and down through my insides, but it felt refreshing and oddly energizing. Only minutes before I drank the stuff, I had been craving a juicy Burger King cheeseburger, but within minutes after drinking this strange water I had no appetite at all -- of course I did just down an entire bottle of water, but still this peppershroom extract seemed to really help decrease my appetite.

The jury is still out on exactly how capsaicin works to suppress the appetite, but many researchers do believe it’s much more than a placebo effect. In fact, a handful of small studies have shown that capsaicin positively reduces the appetite in laboratory rats and mice. If these studies prove out in humans, capsaicin may evolve as an important element of weight loss and overall metabolic health.

Moreover, many well known weight loss supplements do contain some form of capsaicin in their formulas. So it does appear the weight loss industry takes the science of capsaicin quite seriously.

To learn more about SiCap Industries and their natural hot pepper based health products, visit them on the web at (www.sinusbuster.com). Product samples and press kits are available for verified media and medical personnel upon official request.

Posted by Industrial at 05:01 PM | Comments (0)

Galvanon Recognized as a Finalist in the 2005 MS-HUG Annual Awards

Galvanon, the patient experience company, today announced that it was selected as a finalist for the eighth annual 2005 MS-HUG Awards in the Enabling Technologies category for its MediKiosk™ and Customer Value Management Enterprise Server technology.

Maitland, FL (PRWEB via PR Web Direct) January 31, 2022 -- Galvanon, the patient experience company, today announced that it was selected as a finalist for the eighth annual 2005 MS-HUG Awards in the Enabling Technologies category for its MediKiosk™ and Customer Value Management Enterprise Server technology. The honors are awarded by MS-HUG, a membership community of the Healthcare Information and Management Systems Society (HIMSS), and recognize independent software vendors that develop solutions on Microsoft technology for the healthcare industry. Award contestants are evaluated on the extent to which they provide significant business benefits to healthcare organizations and improve patient care.

Galvanon’s MediKiosk is a patient self-service kiosk that automates patient registration and check-in processes. Hospitals and physician practices use MediKiosk to identify patients at check-in, gather necessary forms and signatures and collect co-payments and outstanding balances. By using this self-service kiosk solution, healthcare organizations realize shorter patient wait times, less redundant paperwork, improved staff productivity and increased patient satisfaction.

MediKiosk operates on Galvanon’s Customer Value Management (CVM) Enterprise Server, a common platform that facilitates the seamless exchange of data between MediKiosk and Galvanon’s other solutions, including Online BillPay, Pre-Registration and Membership Manager modules.

“One of the biggest challenges that healthcare organizations face is balancing the desire to increase patient satisfaction with the need to control costs. Our self-service approach strikes this balance with technology designed to improve the way that patient information is gathered, stored and delivered throughout the care process,” said Clynt Taylor, CEO of Galvanon. “It is truly an honor to be recognized by Microsoft for our efforts, and we applaud them for acknowledging the transforming impact that technology can have on the healthcare industry.”

“Galvanon demonstrates its commitment to the healthcare industry with innovative solutions like MediKiosk, leveraging Microsoft technology to improve staff productivity and increase patient satisfaction through a more efficient and automated registration and check-in process,“ said Steve Shihadeh, general manager, Microsoft Healthcare and Life Sciences. “We are pleased to recognize Galvanon’s efforts to drive integrated communication and collaboration solutions that enhance patient care and help to control costs.”

Galvanon will demonstrate its products with other finalists in the Microsoft booth at the HIMSS 2005 Conference & Exhibition from February 14-17 in Dallas. Winners will be announced in the theater at the Microsoft booth (#3035) at 4 p.m. on Tuesday, February 15.

About Galvanon, Inc.
Galvanon helps healthcare organizations enhance the patient experience at home, in the hospital and in the physician’s office through innovative solutions such as kiosks, Web self-service applications and technology that streamlines everyday patient interactions and improves patient flow through the healthcare process. For more information, visit www.galvanon.com/healthcare.

Other product and company names herein may be the property of their respective owners.

Press contact:
Cathi Hilpert
407 667 0669

Sales Contact:
Gary Anthony
817-832-1060

Posted by Industrial at 04:58 PM | Comments (0)

January 30, 2022

Amersin Announces 30% Increase in Ribavirin Production to Meet Market Demand

Amersin is a public company listed on the US OTCBB under the trading symbol AMLS and in Germany on the Frankfurt Exchange under the trading symbol HUQ. Its subsidiary is increasing production of the antiviral Ribavirin in response to market demand created, in part, by recent human cases of avian influenza (H5N1)

New York, NY (PRWEB) January 30, 2022 -- Amersin Life Sciences Corporation (OTCBB: AMLS), announced today that its subsidiary, Hubei Tongji Benda Ebei Pharmaceutical Co. Ltd. (HBPharma), will increase production of Ribavirin injections by 30% in response to market demand.

Ribavirin is a systemic antiviral sold under the brand names Copegus®(1),and Rebetol®(2) in the United States, under the brand name Virazol®(3) in the United States and Canada and as Tribavirin in other parts of the world. It is has been used to treat severe viral pneumonia in infants and young children and, in combination with other agents such as Interferon alfa-2b or Peginterferon alfa-2b, to treat hepatitis C, a viral liver infection.

“Our Ribavirin injection is used by hospitals in China as a front line viral defense” said Mr. Yiqing Wan, President of the Amersin subsidiary, “This increased demand for Ribavirin seems to result in part from concern regarding the high mortality rate associated with recent human cases of Avian flu in the region. We do not yet have an approved treatment regimen specifically for H5N1 so hospitals will rely in the interim on agents that have proven effective at treating other viruses.”

Lethal outbreaks of the highly pathogenic avian influenza (H5N1) were reported in poultry by several Asian countries last June including: Cambodia, China, Indonesia, Malaysia, Thailand and Vietnam. This was followed by renewed sporadic reports of human cases in Vietnam and Thailand. The World Heath Organization (WHO) confirmed 52 cases of H5N1 resulting in 39 deaths between January 28th, 2004 and January 21st, 2005.
According to Professor Wei Sheng Mao, speaking at a WHO press conference during the 55th session of the Western Pacific Regional Committee, ‘unless an enormous prevention effort is mounted very quickly, the threat of avian influenza may be greater than that of SARS’. He went on to emphasize that prevention and cure will be a long-term task.

“Our subsidiary has one of the largest injection production facilities in China and the capacity to rapidly increase production further should it become necessary” commented Amersin CEO, Mr. Reid Li. “We have increased its R&D; effort in an attempt to develop new pathogen specific antiviral agents to meet the challenges that lie ahead and are committed to strengthening its position as a major player in treating anti-viral respondent diseases in China and abroad.”

About Amersin Life Sciences Corporation:
Amersin is engaged in the acquisition and vertical integration of operating subsidiaries and controlling joint venture interests in China to include all facets of pharmaceutical life sciences from research through raw materials and dosage form production to distribution. Its recent acquisition of a controlling interest in the profitable HBPharma subsidiary is a cornerstone in its plan to expand through strategic acquisition and vertical integration to become one of the leading American corporations to profit from the burgeoning life sciences sector in China. Additional information is available via the web at http://www.amersin.com.

"Safe Harbor” Statement:
This news release contains certain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from forward-looking statements. Information about many risk factors is set forth in Amersin’s periodic filings with the Securities and Exchange Commission including, but not limited to, those risks and uncertainties listed in the sections entitled "Cautionary Note Regarding Forward-Looking Statements” and “Management’s Discussion and Analysis” in Amersin’s most recent Quarterly Report available through the EDGAR filing system at http://www.sec.gov. Amersin is under no obligation, and expressly disclaims any obligation, to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

(1)(2)(3) - trademarks or registered trademarks of their respective mark holders
For more information, please contact:
Howard Milne, Corporate Communications
Amersin Life Sciences Corporation
Voice: 604-881-2899 ext 220
Fax: 604-881-2892

Posted by Industrial at 08:13 AM | Comments (0)

“Understanding USP 797” and “Environmental Controls for Sterile Compounding”

Two technical papers produced by Baxa Corporation – “Understanding USP 797” and “Environmental Controls for Sterile Compounding” are now posted for media and professional access on PublicRelationsNewsroom.com. Since the American Society of Health-System Pharmacists (ASHP) released USP 797 in January 2004 and the National Institute for Occupational Safety and Health (NIOSH) published its 2004 alert on the health risks posed to those working with hazardous drugs, there has been a renewed focus on safety within the hospital pharmacy environment. These papers address the various issues under discussion.

Englewood, CO (PRWEB) January 30, 2022 -- With hazardous drug handling brought to the forefront of public scrutiny in 2004 by the American Society of Health-System Pharmacists (ASHP) USP 797 and a related National Institute for Occupational Safety and Health (NIOSH) Alert, Baxa Corporation has published two related technical papers: “Understanding USP 797” and “Environmental Controls for Sterile Compounding.” Both papers are now posted on www.PublicRelationsNewsroom.com for both professional and media access (click either the ASHP USP 797 tab or the compounding tab if accessing from the home page), according to Greg Baldwin, Chairman and CEO of Baxa Corporation. Baxa is the US distributor of PhaSeal®, the only closed system that prevents the workplace contamination threats as delineated in the NIOSH Alert.

“Understanding USP 797” is found at http://www.publicrelationsnewsroom.com/_wsn/page4.html. This paper is authored by Baxa Corporation’s Michael Hurst RPh, MBA.

Hurst worked for 18 years at Swedish Medical Center in Seattle, WA, in operational management, including positions as IV Supervisor and Assistant Director of Pharmacy. His implementation of a syringe infusion system in 1984 had national implications. For the next nine years Hurst wrote, spoke, consulted and acted as a reference site for syringe infusion installations across the country.

Moving to industry full time in 1994, Hurst joined Baxa Corporation as Vice President of Infusion Systems. His job duties have included customer support for syringe infusion system installations, new business and product development roles, and professional services support for various Baxa pharmacy and nursing product lines. Hurst is currently consulting with a hospital system in the development of a comprehensive USP 797 compliance template that can be applied in other hospital pharmacies.

“Environmental Controls for Sterile Compounding” is found at http://www.publicrelationsnewsroom.com/_wsn/page6.html.

Baxa Corporation, as previously mentioned, offers the only closed system for safe handling of antineoplastic and other hazardous drugs. This system, PhaSeal®, uses dry connections and a built-in expansion chamber to prevent drug aerosol leakage and subsequent transfer into the work environment. As a closed system, it contains hazardous drugs throughout the entire process of drug transfer, preparation, transport, administration and disposal - eliminating the risks of environmental and occupational exposure. The PhaSeal System is currently in use for handling hazardous drugs in more than 200 leading cancer hospitals in the US. The system is also used in progressive hospitals throughout Europe.

A leading provider of devices and systems for the preparation, handling, packaging, and administration of liquid medications, Baxa Corporation manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Headquartered in Englewood, Colorado, Baxa has subsidiaries and sales offices in Canada, the United Kingdom; Denmark, and Germany; and distribution partners worldwide. Further information is available at http://www.baxa.com.

The PhaSeal System is manufactured in Sweden by Carmel Pharma ab of Göteborg, Sweden. Introduced in Europe in 1994, the PhaSeal System is now used in most Swedish hospitals, with its benefits documented by a significant body of scientific research on the health risks associated with the preparation and administration of cytotoxic drugs. The PhaSeal System is protected by a comprehensive patent portfolio in the U.S., European Union and Japan. For more information on Carmel Pharma, please visit http://www.carmelpharma.se.

Contacts:
Marian Robinson, Vice President, Marketing
Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157

Maggie Chamberlin Holben, APR, Absolutely Public Relations
303.984.9801, 303.669.3558

Posted by Industrial at 08:10 AM | Comments (0)

January 28, 2022

CLSR Head Massage Day - Saturday 9th April 2005

Central London School of Reflexology (CLSR), Britains Top Reflexology College, will be holding it's next 'Head Massage Day' on Saturday the 9th of April 2005

(PRWEB) January 5, 2022 -- Central London School of Reflexology (CLSR), Britains Top Reflexology College , will be holding it's next 'Head Massage Day' on Saturday the 9th of April 2005 at it's Covent Garden Premises in London.

Head massage is a very useful skill to have and has many benefits including improved circulation to the Brain , together with soothing stimulation of the nerves in the Head and neck. It is also an exceedingly useful Therapeutic Intervention in those with a history of Migraines and Cluster Headaches ; and can safely be administered (after suitable Training) to one's partner or loved one. The CLSR course also covers ‘Cross Reflexes’ and many other interesting phenomena.

CLSR has a maximum of 16 seats in this class, so please kindly book early as there are only a few places left. The Course Fee is £125 (US$240 or €180)inclusive of Lunch and an Official CLSR Certificate. The next CLSR 'Head Massage Day' takes place on July the 1st 2005. Please kindly visit www.ReflexologySchool.co.uk for more details concerning this and future courses.

About Central London School of Reflexology (CLSR):
Central London School of Reflexology (CLSR) is one of the longest established Reflexology Schools in the United Kingdom , with a Solid International Base.

CLSR was established in early 1989 to effectively train and mentor Independent Practitioners of Reflexology to the Highest Professional Standards. Our Core Curriculum currently meets (and possibly exceeds) the Foundation Requirements set out by the House of Lords Report (2000) on Complementary and Alternative Medicine (CAM), and the Reflexology Forum.

This will ensure that all CLSR Graduates will be appropriately qualified to take full advantage of New Career Opportunities which are swiftly becoming available to Reflexologists all over the globe ,as the World moves towards a more Integrated Approach to Healthcare Delivery. We have consistently gained a highly unique reputation for providing one of the World's most Comprehensive, Ethical, Professional, Informative and Cost-Effective Reflexology Courses available.

Our 'Tailored' Government-Approved (ABC) Diploma Courses in Reflexology are held over nine months and on graduation CLSR Practitioners in Reflexology will be eligible to join the Association of Reflexologists (AoR), becoming entitled to use the letters MAR after their names.

Additionally, Central London School of Reflexology is currently the only Accredited Training Institution by the Faculty of Refloxology (FoR) ; an International Caucus of Seasoned Consultants in Advanced Reflexology. In most European Countries and International States which reciprocally recognise British Qualifications, most CLSR graduates should not have difficulty integrating seamlessly into their own Local Healthcare Systems.

CLSR Graduates will also (subject to satisfactory conditions) be ethically listed on an International Referral Database, which is continuously updated and made freely available globally to the Medical Profession , Qualified Healthcare Practitioners and other members of the public who may wish to seek the services of Qualified Reflexologists.

CLSR has formidably and flawlessly laid the Selfless Foundations for many other Independent Reflexology Schools to freely model and emulate.

CLSR is fully committed to finding gainful employment for Successful Graduates in various organizations like Health Clubs, Hotels, Holiday Resorts, Health Farms, Spas, Hospitals, Hospices, Clinics, Elderly Care Homes, Day Centres, Private Health Establishments, Beauty Parlours and many other Institutions.

CLSR is conveniently situated in the heart of Covent Garden in London’s West End and located close to Charing Cross, Leicester Square and Covent Garden Underground Tube Stations.

Understanding Reflexology:
The healing art of Reflexology has been practiced for many thousands of years. One of the earliest recordings of this therapy is a painting within the tomb of the physician in ancient Egypt dated 2300BC and illustrated Reflexology treatments being performed on the feet and hands. When Native Americans practiced a form of Reflexology they believed that energy is exchanged from the earth through the feet and considered how important it is that there are no blockages in the feet to stop this flow of energy.

Contact us at www.reflexologyschool.co.uk for a prospectus.

Posted by Industrial at 08:42 AM | Comments (0)

Computerized Medical Records – Heart Sounds and Murmurs Can be Remembered Forever

Biosignetics Corporation has developed software that can store and process digitally recorded heart sounds and help to identify heart murmurs. This can be particularly useful during the routine cardiac exam known as heart auscultation. Company continues its research and currently offers educational and non-clinical research versions. Phonocardiograph Monitor software had received FDA clearance to market in October 2004. Software can be utilized to improve the efficiency and functionality of the cardiac asucultation. With Japan breathing heavily behind - God Speed Biosignetics of New Hampshire!

(PRWEB) January 28, 2022 -- President Bush is highlighting the wave of the future in medicine — computerized records to reduce cost and errors.

"We've got 21st-century medical practices but 19th-century paperwork system," G.W. Bush said Wednesday during a visit to the National Institutes of Health.

Indeed we do. For example in cardiology and family medicine there is no established practice of keeping permanent sound data from the cardiac exam (heart auscultation).

Dr. Aubrey Leatham's (Great Britain) new classification of mid-systolic ejection murmurs versus pansystolic regurgitant murmurs was based on his graphic analysis. Leatham A: Auscultation of the heart. Lancet 1958;II:702–708, 757–765. But it changed the way clinicians approached the bedside diagnosis of valvular disease and contributed to decision making for cardiac surgery. We think that computerized analysis can definitely be helpful.

"So there's a better way to enable our health care system to wring out inefficiencies and to protect our patients.", said the President who had also visited Cleveland Clinic to promote his initiative. Cleveland Clinic is internationally known as cardiology center of excellence.

Biosignetics Corporation is revolutionizing the same field - a two century old art of heart auscultation. We offer physicians to record heart sounds digitally and to process them using what we call Visual or Digital Stethoscope Software.

The recording process was perfected by the company scientists and now allows doctors to perform digital auscultation during the regular cardiac exam. Heart sounds can be recorded in parallel and can be stored, replayed and subsequently processed to identify key features and imperfections. This process can also be utilized in telemedicine. Storage format called Heart Energy Signature is currently patent pending. Company's flagman Phonocardiograph Monitor software (BSignal) has received FDA clearance for market in October 27, 2004.

http://www.bsignetics.com/products.htm

Biosignetics had recently completed its research software that allows an effective noise removal from the digitally recorded sonograms or phonocardiograms (wave sound files). "Noise reduction procedure can help us to effectively deal with the practical issues that slow down electronic stethoscope acceptance by the medical community," indicated Dr. Vladimir Polyshchuk, Biosignetics co-founder. "We can work with low quality sound recordings and extract maximum amount of useful information from them," he added.

Noise removal method developed by Biosignetics is unique, because it allows keeping all the useful content of the signal and does not alter the shape of the heart sound signal. Right now company is testing this technique while using different electronic stethoscopes: Welch Allyn, Meditron, Littmann, i-Stethos, Babe Monitor.

Japaneese medical researchers are now also promoting a digital device -- a "visual stethoscope" -- that would allow doctors to see as well as hear heart sounds, with the additional advantages that the output could be stored, attached to patient records and reviewed by more than one doctor.

"This would make the information we get from heart sounds more objective," says Dr. Hiroshi Makino of Hamamatsu University in Hamamatsu City, Japan. "Now, I listen and then you listen, but we may hear different things or disagree. With this technology, we can reach a diagnosis through a consensus of many doctors."

Biosignetics Corporation is looking for additional VC funding, well recognized volunteer PR speaker and medical researchers and physicians to work on collaborative projects.
Research donations are also accepted.
God Speed Biosignetics!

Additional relevant newslinks:
http://www.bsignetics.com/news.htm
A New Digital Stethoscope
Movers and Shakers
New Heart Research Poised to Help Millions
Heart Auscultation

Posted by Industrial at 08:39 AM | Comments (0)

Seneca Medical Inc. Announces Expansion of Operations Through Acquisition of Shelby Warehousing Inc.

Tiffin, Ohio – Seneca Medical Inc. announces the acquisition of the assets and operations of Shelby Warehousing Inc., located in Shelbyville, Ind. This purchase further expands Seneca Medical’s market coverage and service capabilities to include Indiana, southwest Ohio and northern/western Kentucky.

Tiffin, OH (PRWEB) January 28, 2022 -- Seneca Medical Inc. announces the acquisition of the assets and operations of Shelby Warehousing Inc., located in Shelbyville, Ind. This purchase further expands Seneca Medical’s market coverage and service capabilities to include Indiana, southwest Ohio and northern/western Kentucky.

“This investment is intended to strengthen our regional distribution capabilities in a very important geographical service area,” said David Myers, vice president of sales and marketing for Seneca Medical.

Shelby Warehousing provides public warehousing and third party logistics services for customers in multiple market segments. The company supports customers with an 80,000 square foot warehouse and office facility in central/southeast Indiana. Shelby Warehousing will continue to operate as a third party logistics provider and service existing customers, and the company will expand its business to include manufacturers of medical-surgical products, leveraging Seneca Medical’s excellent relationship base in this industry.

Through this acquisition, Seneca Medical gains additional experienced and dedicated employees and a facility that is ideally situated to support the expansion of Seneca Medical’s core operations. Plus the purchase demonstrates the company’s commitment to the community, Myers said.

“We made a conscious decision to buy to show that we intend to stay in this market. During our planning process and customer interviews, a number of contacts highlighted the importance for Seneca Medical to demonstrate our commitment to the region. Healthcare is really a regional marketplace, so investing in the region was a fairly simple decision,” he said.

By mid-year, Seneca Medical plans to utilize part of the facility for its core medical surgical distribution business and expand with business growth. Due to previous investments in additional sales and marketing personnel, Seneca Medical’s customer base has grown in the past two years in Indiana, southwest Ohio, and northern Kentucky; Seneca Medical’s acquisition of Shelby Warehousing simply solidifies the company’s commitment to serving healthcare customers in this growth market. As customers continue to migrate to Seneca Medical’s model of distribution services, it is anticipated that the company’s work force will increase in both Shelbyville and its homebase in Tiffin, Ohio, to support its growth.

The company hopes to employ five to 10 new workers in Shelbyville by the end of 2005 with the potential eventually to have 40 to 50 workers at the facility, Myers said.

Dan Theobald, executive director of the Shelby County Development Corp., a private economic development group in the county where Shelbyville is located, helped Seneca Medical locate the warehouse facility. The SCDC is a member of The Indy Partnership, a regional economic development organization that markets the Indianapolis Region.

Seneca Medical is a full service independent, privately owned and operated regional provider of medical/surgical supplies, medical, equipment and complementary support services. Founded in 1990, Seneca Medical has consistently expanded through its dedication to a customer service-focused distribution model. Through a stock ownership plan launched in 1998, the company’s more than 280 current and retired employees own 90 percent of Seneca Medical’s stock. This employee-driven participation generates unparalleled “personalized” distribution services to Seneca’s customers.

Seneca Medical, headquartered in Tiffin, Ohio, provides a wide spectrum of product distribution and support services to the health care continuum throughout Indiana, Kentucky, Michigan, Ohio, Tennessee, West Virginia and surrounding states. From its three distribution facilities, in Tiffin, Ohio, Ripley, W.Va. and Knoxville, Tenn., Seneca Medical currently serves hospitals, surgery centers, physician offices, long-term care facilities, governmental health departments, sports medicine and industrial health services customers.

Seneca Medical has well established distribution relationships with more than 650 high-quality market-leading business partners who manufacture the following range of product groups:
•Medical Surgical Supplies
•Medical and Diagnostic Equipment
•Pharmaceuticals
•OTC Products
•Laboratory Supplies
•Paper Products
•Office Furniture
•Sports Medicine Supplies and Equipment (available for nationwide distribution)
•And More

If more information is desired about Seneca Medical Inc., please reference our Web site at www.senecamedical.com.

Contacts:
Seneca Medical Inc. – David Myers, Vice President, Sales and Marketing (419) 447-0222 www.senecamedical.com

The Indy Partnership – John Walker, Communications/Media Manager (317) 464-5413 www.indypartnership.com

Posted by Industrial at 08:37 AM | Comments (0)

Carotid Stents Market to Reach $180 Million by 2010

Carotid Artery Stenting (CAS) has recently emerged as a popular alternative to endarterectomy for the treatment of carotid atherosclerosis. The recent approval, by the FDA, of carotid artery stents has initiated a global market for those devices. According to a new report by Medtech Ventures, the market for Carotid Artery Stenting is poised for phenomenal growth. Forecasts by industry executives estimate the market to reach US$180 million by 2010.

(PRWEB) January 28, 2022 -- Treating stroke-related circulatory problems with interventional devices is one of the most promising emerging medical device markets. In ten years, stroke likely will be a treatable condition in the same way that myocardial infarction is today.

Approximately, 250 per 100,000 of developed world population are affected by stroke every year. In the US the number of stroke sufferers is estimated at 700,000 every year (500,000 new & 200,000 recurrent), of whom 280,000 die as a result of the attack. Carotid artery stenosis can be linked directly to 25% of all ischemic strokes incidences.

Endovascular stent treatment of carotid artery atherosclerotic disease is currently being positioned as an alternative for vascular surgery, especially for patients who are at high risk for standard carotid endarterectomy.

Carotid stenting systems, of which the first one was approved by the FDA for marketing in the US at the end of August 2004, have been available on international markets for the past couple of years.

At the end of 2004 the global market for those devices have been estimated at close to US$10 million. The fan fair surrounding the approval of Guidant's carotid stenting system in the US has kicked off the market to a good start.

Companies active internationally in this market include the big five: Abbott, Boston Scientific, Guidant, Johnson & Johnson and Medtronic. Only Guidant has its product currently approved in the US while the rest are placing their products as investigational devices.

This situation is likely to change during 2005 when the potential approval of other companies product lines is expected.

Based on current technology situation, published company and investment analysts forecasts and feedback from industry executives and thought leaders we forecast the market to reach US$180 million, globally, by the end of the decade.

Posted by Industrial at 08:35 AM | Comments (0)

Bob Zaloga Named Director of Emerging Technologies at Media Brokers International

Media Brokers International (media-brokers.com), a recognized player in the Advertising related media buying and planning industry, recently named Bob Zaloga to serve as their Director of Media Services – Emerging Technologies. He will be responsible for establishing the company's strategic direction and leading the sales and marketing efforts related to emerging technology based companies.

(PRWEB) January 28, 2022 -- Media Brokers International (http://www.media-brokers.com), a recognized player in the Advertising related media buying and planning industry, recently named Bob Zaloga to serve as Director of Media Services – Emerging Technologies. He will be responsible for establishing the company's strategic direction and leading the sales and marketing efforts related to emerging technology based companies.

“Bob compliments our team with a seasoned track record of successfully managing and developing technology based organizations”, said Ben Johnston, Media Brokers International CEO & President. “Bob's technical savvy combined with his keen awareness of the marketplace were instrumental in deciding to move forward in the emerging areas. His insight will contribute to us achieving our growth goals and getting to the next level. I am delighted to welcome him aboard”

Zaloga, based in Alpharetta, brings to Media Brokers more than 20 years of management and sales experience in the high-growth, integration, and emerging sectors. Most recently he was the executive in charge of Professional Services for an industry leading Internet-only financial services firm and has held several senior strategy & marketing executive roles in technology. His most notable accomplishment was co-developing a life-cycle management (managed services) model that grew to more than $650 MM and 2,500 employees in less than 21 months.

Prior to founding Business Process Applications (a management consulting firm specialized in Project Management) Mr. Zaloga was employed by General Electric's Industrial Power Systems group and was focused on Nuclear fuel and operations. He holds a master’s degree in Business Administration with a concentration in General Management, Finance, and International Business from Georgia State University’s Executive MBA Program; and a Bachelor's of Science in Marine Engineering with a focus on advanced mathematics and physics from Massachusetts Maritime Academy. He is a member of several professional organizations including “Who's Who in American Business and Technology”.

“Media Brokers International is more than appealing especially from the stand-point of positioning. Given the recent rebound associated with the technology sector, MBI's ability to execute, and their relationship orientation make this an opportunity of a life-time. I look forward to helping a variety of companies reach and maintain their brand leadership while developing the technology business within MBI.”

About Media Brokers International
Media Brokers International (http://www.media-brokers.com), founded in 1992 and based in Alpharetta, Georgia, is a full service media buying and planning agency that delivers premier media placement at significantly discounted cost. MBI currently has over 500 clients and has placed ads in over 800 magazines, billboard and transit, the major television and cable networks, and most national daily newspapers. MBI's clients maintain annual billings between $50,000 and $20,000,000, and participate in a variety of industries including but not limited to, health care, nutrition supplements, food & wine, fashion, beauty, fitness, medical products, and technology. As a value proposition, MBI expands an organization's advertising reach via a service set that provides enhanced circulation and premier placement typically at significantly discounted rates.

Posted by Industrial at 08:33 AM | Comments (0)

January 27, 2022

New Report on Artificial Disc Replacement Now Available - Artificial Discs: The Spine Surgeons' View™

The Charite™ Artificial Disc was recently approved for use in the U.S. Approval of other artificial disc systems will soon follow. These implants may dramatically alter the spinal market over the next few years. With predictions varying widely, MDMR® surveyed spine surgeons to understand their views on the impact of artificial discs and to learn their specific suggestions to manufacturers regarding the development and commercialization of next-generation implants. Representing 35 surgeons and nearly 1,200 artificial disc procedures, this survey of Charite™ Artificial Disc, ProDisc®, FlexiCore™ and Maverick™ clinical investigators is the most comprehensive look to-date at the current generation of lumbar artificial discs.

Austin, TX (PRWEB) January 27, 2022 -- Medical Device Market Research, LLC - MDMR®, a leading provider of decision-support and market intelligence to the medical device industry, announces the publication of a new report, Artificial Discs: The Spine Surgeons' View™

Representing 35 surgeons and nearly 1,200 artificial disc procedures, this survey of Charite™, ProDisc®, FlexiCore™, and Maverick™ clinical investigators is the most comprehensive look to-date at the current generation of lumbar artificial discs. The surgeons who know these products best answer questions regarding:

Market Dynamics
•How will the availability of artificial discs impact surgeon treatment of lumbar fusion patients over the next two years?

Decision Factors
•What are the six key decision factors that will influence spine surgeons choice of discs as more artificial discs become commercially available?

Competitive Positioning
•What are the differentiators for each artificial disc system?
•What are the perceived advantages and disadvantages of each disc?

Challenges and Suggestions
•What are the greatest challenges of disc arthroplasty in terms of access, approach, disc space preparation, sizing, templating, insertion, placement, and revision?
•What are the surgeons' suggestions to manufacturers to address these challenges?
•What are the critical aspects of disc arthroplasty training and who should provide the training?

“This surgeon-based survey report is unique as it provides specific actionable intelligence of value to all companies involved in the development and commercialization of current and next-generation artificial discs, as well as competitive fusion and non-fusion spinal technologies”, explained Greg Heikes, Director of Research at MDMR®

To learn more about Artificial Discs: The Spine Surgeons' View™, please call 800-889-3130 (512 358-7200 outside the U.S.) or visit MDMR® online at www.mdmr.net

Posted by Industrial at 02:02 PM | Comments (0)

Independent Review Organization: AllMed Healthcare, an Independent Review Organization (IRO) Specializing in Medical Review and Peer Review

AllMed Healthcare Management, an Independent Review Organization (IRO) providing medical review and peer review services to healthcare payers, providers, claims managers, and hospital groups, has released its Winter 2004/2005 edition of Medical Review News.

(PRWEB) January 27, 2022 -- AllMed Healthcare Management, an Independent Review Organization (IRO) providing medical review and peer review services to healthcare payers, providers, claims managers, and hospital groups, has released its Winter 2004/2005 edition of Medical Review News.

The newsletter contains the following articles of interest to Claims Managers, Claims Administrators, and Medical Directors at Health Plans, Third Party Administrators, Utilization Review Companies, and Medical Management Companies.

Outlines of the newsletter articles appear below. Click below to view and subscribe to the AllMed Newsletter

http://www.allmedmd.com/company/newsletter/05Jan/pr/ .

Article #1—Cancer Treatment Claims Management / Claims Administration
* What is the difference between protocols for scientific experiments and medically accepted protocols for treatment?
* What are the 4 major types of cancer treatment?
* What is the role of an Independent Review Organization (IRO) in determining whether a cancer treatment is sanctioned or experimental?
* How can AllMed, as an Independent Review Organization (IRO) work with you in Cancer Treatment medical review situations?

Article #2-- Does Shockwave Therapy Help Plantar Fasciitis
* How is Plantar Fasciitis caused?
* What are the typical treatment options for Plantar Fasciitis?
* How would external medical review specialists, such as AllMed, view an experimental treatment such as Shockwave Therapy – medically necessary or not?
* How can an investment in a medical review for Shockwave Therapy save an organization the cost of a 5-figure treatment?

Article#3-- Managing Evidence-Based Self Insurance Plans
* What are the current trends in self-insurance for large organizations?
How can AllMed, as an Independent Review Organization (IRO), assist self-insurance plans with ERISA Mandated medical reviews?
* How can Independent Review Organizations (IRO) such as AllMed assist medical management companies in complying with their legal duties towards patients?
* What services can AllMed, as an Independent Review Organization (IRO), provide a medical management company?

AllMed provides medical opinions that quickly resolve complex problems -- saving money while protecting the integrity of patient care. AllMed will review chart notes and operative reports to render objective written opinions; help you reach the right decision while reducing legal risk; apply your plan language to the case, if appropriate, give you direct access to our physicians for questions and follow-up on reviews; and supply clear, professional and easy-to-read documentation. AllMed also applies the same high quality standards to its hospital peer review, pharmacy review, medical bill auditing, and medical director review services.

Click the link below to view and subscribe to the AllMed Newsletter
http://www.allmedmd.com/company/newsletter/05Jan/pr/ .

About AllMed:
Allmed reviews claims for issues of medical necessity, standard of care, experimental / investigational, hospital quality management, code unbundling, fraud, and other issues that affect healthcare decision-making.

Posted by Industrial at 08:31 AM | Comments (0)

January 26, 2022

Riverview Psychiatric Center Subscribes to Advanced Technology for Patient Safety and Cost Containment

Saferating Inc. announces today that Riverview Psychiatric Center(RPC) of Augusta Maine (formerly Augusta Mental Health Institute) purchased a suite of reporting tools utilizing the power of Paperless Form Technology (PFT) for 2 ambulatory clinic sites. RPC utilizes Saferating.com to manage pharmaceutical samples at two clinics.

Lewiston, Maine (PRWEB) January 26, 2022 – Riverview Psychiatric Center subscribed to Saferating’s Paperless Form technology for its two ambulatory clinics in Augusta and Portland, Maine. Staff now has instant web access for secure recording the receipt of sample medications received from pharmaceutical sales representatives. Regulations from both state and JCAHO require that if samples are utilized for patient care, then a method to log incoming samples must be kept. The required documentation must include lot and expiration dates for the sample drugs. Furthermore, upon dispensing the samples, the outgoing samples must be labeled by a licensed prescriber with the information typically supplied by a retail pharmacy.

RPS staff will now utilize Saferating’s PFT and a custom form to log incoming samples, and a second form which will supply staff with both a label-like document and a documented note for the patient’s medical record. Administrators will have secure access to databases for tracking and real time access in the event of a drug recall. Follow-up and analysis will utilize Saferating’s powerful query engine and report generator to enhance its system improvement and contribute to compliance with HIPAA and JCAHO standards.

Because Saferating’s PFT forms are intuitive, yet thorough, it is expected that this new technology will save extensive labor hours and the associated costs. Riverview Psychiatric Center is proud to take this step in patient safety, reporting enhancement, and cost containment. Learn more at www.Saferating.com

About Saferating Inc
A leader in Paperless Form Technology solutions for the healthcare industry, Saferating.com provides HIPPA compliant applications to document and report clinical activity. Saferating has developed other solutions for meeting JCAHO requirements for reporting of Adverse Drug Reaction, Medication Errors, Anticoagulation Medication Tracking, Incident Reporting, Patient Satisfaction Surveys, and Competency Assessment. saferating.com’s solutions improve patient care, reduce costs by eliminated paper-based forms, and eliminated redundant data entry. Saferating.com is based in Lewiston Maine. For more information, please visit www.Saferating.com

About Riverview Psychiatric Center
RPC (formerly Augusta Mental Health Institute). In 1834 the Maine Legislature passed a resolve to establish the Maine Insane Hospital and appropriated $20,000 for this purpose.

The hospital was built across the river from the Capitol building. The reason for this was so that the Governor and the Legislature would never forget the hospital. Today the State of Maine has built a 92-bed civil and forensic psychiatric treatment facility to replace the existing 161-year-old state hospital, the Augusta Mental Health Institute (AMHI). The new facility opened in late 2004. The new facility, Riverview Psychiatric Center, offers a state-of-the-art treatment environment that supports healing, respect, and safety.

Posted by Industrial at 08:29 AM | Comments (0)

January 25, 2022

Fingerprint Recognition Technology Makes Door Lock Keys a Thing of the Past

This release announces the new M28 Fingerprint Door Lock. An innovative security device that combines a conventional door lock with high precision biometric fingerprint recognition technology.

(PRWEB) January 25, 2022 -- Doors have locks to keep unauthorized people out of course. Unfortunately, the reality is that door keys get lost, duplicated, or even worse… stolen. MATA BioTech has developed a biometric door lock designed to recognize the authorized user’s fingerprint in order to open a door, making conventional keys unnecessary.

In these troubling times when security is of critical concern, the M28 Fingerprint Door Lock delivers an improved solution to an age old dilemma. The M28 is easily installed on just about any standard door and provides businesses and homeowners with peace of mind, knowing that only the fingerprints of authorized users can access the lock.

Forget about fumbling for your keys. Simply place your finger on the door lock and in less than 3 seconds, it recognizes you and you’re in. Never worry about losing keys or unauthorized duplication…ever! More importantly, secure any room with the most unique key on earth… your fingerprint.

How does it work? The user gently presses their finger against the sensor surface. This sensor is connected to a microprocessor inside the lock. The information from the scan is analyzed. If verification of the fingerprint is successful, the lock mechanism opens allowing you to turn the handle and open the door. Initially, a fingerprint is scanned and enrolled right on the lock, and it is instantly converted into a mathematical template. This template is a data representation of the fingerprint. It is stored in the memory of the lock, and later used during verification.

“Its a common problem that happens to all of us; we misplace, lose, or have even had our keys stolen,” said Dr. Olman Mata president of MATA BioTech. “It’s a simple fact, keys, pin codes, passwords, or proximity cards are convention access methods that can be stolen, lost, or passed on to unauthorized users. Biometric methods cannot be stolen lost or copied. Your fingerprint is unique and no one can steal that from you.”

The M28 Fingerprint Door lock can store up to 10 fingerprints, and has the unique ability to enroll and delete individual fingerprints from its memory without having to erase all stored fingerprints. All this is easily and quickly done right on the lock, without the need of a computer link, or technical knowledge. Three identical mechanical keys are included to manually open the door if so desired.

Very easy to install and even easier to operate. It can replace just about any door knob or door handle using the door’s existing bore hole. Solid heavy duty construction yet stylish in design, it is made from durable zinc-alloy metal. This lock is suitable for home or office and requires no hard wiring or complicated door modifications. The M28 is powered by four standard AA alkaline batteries that are included. Battery life is 8 months to a year depending on usage. When the battery power is low, the unit produces an audible warning signal. The lock will even operate dozens of times before the batteries are fully depleted. When the batteries are removed and replaced, the enrolled fingerprints remain in memory.

Dr. Olman Mata integrates his knowledge of human biology and electronic circuitry to design and manufacture affordable innovative biometric devices. The company is also known for the G10 fingerprint drawer lock, and they are also developing a biometric briefcase with fingerprint recognition technology. MATA BioTech is based in Southern California. For more information, visit www.matabiotech.com or call 1-877-782-4336

Posted by Industrial at 08:08 AM | Comments (0)

Concerned Consumers are Seeking Alternatives to Drugs for Their Pain

The list of potentially dangerous side effects associated with the overuse of prescription and OTC pain relief drugs is growing, but what alternatives do consumers have?

Alpharetta, GA (PRWEB) January 25, 2022 -- The list of potentially dangerous side effects associated with the overuse of prescription and OTC pain relief drugs is growing, but what alternatives do consumers have?

Bruder Healthcare Company has introduced a new line of OTC products that deliver doctor recommended pain relief treatments without the risk of side effects or interference with prescription or OTC drugs. New THERMALON™ Microwave Activated Moist Heat Wraps and Sleeves represent a safe and easy way for consumers to reduce their total dependence on drugs for pain relief.

When microwaved for a minute, reusable THERMALON™ Microwave Activated Moist Heat Wraps and Sleeves safely deliver a moist heat therapy treatment. Moist heat penetrates deep quickly to increase blood flow, relax tight sore muscles and reduce painful inflammation. Medical professionals use moist heat treatments in clinics to relieve pain … now consumers can apply these same treatments safely and conveniently at home. The patented Orthobeads™ in THERMALON™ are self-hydrating and are specially formulated to remain odor and bacteria free. Adding water is never necessary. Anatomical designs make application easy while their portability allows normal activity during a recommended twenty-minute treatment. The unique pull-on Sleeves can also be used when Cold Therapy is prescribed or preferred. Use while exercising, pre or post sports and outdoor activities or before retiring. The sleeves help make prescribed exercises easier, more effective and far less painful. Economical to use, the soft and conformable wraps and sleeves are washable and feature a full one-year warranty.

Newly introduced HTA (Heat Therapy Activated) Pain Relief Spray is an all-natural, clinically proven topical analgesic specifically formulated for use with heat therapy. Popular pain relief ointments and patches in stores today are harsh, often smelly counter-irritants containing the warning “do not bandage or use with a heating pad”. HTA Pain Relief Spray is different … it has been formulated to enhance the proven effectiveness of medically recommended heat therapy. The natural extracts in HTA, when activated by heat, penetrate directly to the source of the pain. There is no waiting, no odor, no staining! HTA comes in an easy-to-use spray applicator.

Consumers now have a two new drug free alternatives to help manage their pain. With THERMALON™ and HTA they can use fewer pills; avoid dangerous electric wires, offensive odors, greasy ointments and expensive disposable patches.

For more information visit www.thermalon.com

Founded in 1986, Bruder Healthcare of Alpharetta, GA designs, manufacturers and markets natural analgesic products.

Contact:
Sharon Burkart
Phone 1-888-827-8337 ext. 210
Fax 1-770-521-5557

Posted by Industrial at 08:02 AM | Comments (0)

January 24, 2022

Amersin Life Sciences Announces Contract with China’s International Tsunami Relief Program

Amersin, a public American holding company, supplies pharmaceuticals for Sri Lanka tsunami relief program under 6.4 million RMB contract through its Chinese subsidiary.

New York, NY (PRWEB via PR Web Direct) January 24, 2022 -- Amersin Life Sciences Corporation (OTCBB: AMLS), announced today that it’s subsidiary, Hubei Tongji Benda Ebei Pharmaceutical Co. Ltd., has entered into a sales contract valued at 6.4 million RMB with the Ministry of Health’s China Medicine and Technology Foreign Co-operation Co. Ltd.

“This contract is to supply pharmaceuticals to aid Sri Lanka as part of the China’s tsunami relief program,” said Mr. Yiqing Wan, President of the Amersin subsidiary, "we are very pleased to be selected as a supplier and to be part of this international tsunami relief effort. It further illustrates our strong product reputation and relationships with governmental and non-governmental organizations (NGO’s) alike. We would of course prioritize to participate further if called upon or opportunities arise to support other initiatives.”

About Amersin Life Sciences Corporation:
Amersin is engaged in the acquisition and vertical integration of operating subsidiaries and controlling joint venture interests in China to include all facets of pharmaceutical life sciences from research through raw materials and dosage form production to distribution. Its recent acquisition of a controlling interest in the profitable Hubei Tongji Benda Ebei Pharmaceutical Co. subsidiary is a cornerstone in its plan to expand through strategic acquisition and vertical integration to become one of the leading American corporations to profit from the burgeoning life sciences sector in China. Shareholders can access further information via the company's website at www.amersin.com.

"Safe Harbor” Statement:
This news release contains certain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from the forward-looking statements contained herein. Detailed information about many risk factors are set forth in Amersin’s periodic filings with the Securities and Exchange Commission including, but not limited to, those risks and uncertainties listed in the sections entitled "Cautionary Note Regarding Forward-Looking Statements” and “Management’s Discussion and Analysis” in Amersin’s most recent Quarterly Report on Form 10-QSB. All documents are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov or the Amersin web site at www.amersin.com. Amersin is under no obligation, and expressly disclaims any obligation, to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:
Howard Milne, Corporate Communications
Amersin Life Sciences Corporation
Voice: 604-881-2899 ext 220
Fax: 604-881-2892

Posted by Industrial at 07:57 AM | Comments (0)

January 23, 2022

Morena Vista Trading Sues Emerging Pharmaceutical Company, Kinetana, for $6 Million for Intentional Misrepresentation and Breach of Contract

Morena Vista Trading LLC files suit against Kinetana International BioTech Pharma Limited in California State Superior Court seeking damages of $6 million for intentional misrepresentation, breach of contract, civil racketeering and corrupt organization claims. Kinetana is a pharmaceutical company publicly traded on the Growth Enterprise Exchange of the Hong Kong Stock Exchange with principal places of business in Edmonton, AB Canada and Hong Kong.

(PRWEB) January 23, 2022 -- Morena Vista Trading LLC filed suit this week against Kinetana International BioTech Pharma Ltd., a publicly traded company on the Growth Enterprise Market of the Hong Kong Stock Exchange/ Kinetana Holdings/ Kinetana Group Inc., of Edmonton, AB Canada/ it’s subsidiaries and key board members and shareholders, Dr. Yun K. Tam, Dr. Nuzhat Tam-Zaman and Mr. Sui Leung Yeung, in the California State Superior Court (case 04CC12637) seeking damages and relief of $6 million, while citing instances of intentional misrepresentation, breach of contract, civil racketeering and corrupt organization claims.

Morena Vista Trading (dba Kairos-Meade), a California based strategic business development & marketing company, formed a joint venture with Kinetana in April of 2004 to establish sales of Kinetana products in the U.S. and Canada.

Morena Vista Trading is seeking damages and relief in the amount of $6 million for intentional misrepresentation and breach of oral and written contracts resulting in loss of invested monies, business opportunities, unjust hardship due to willful misrepresentation and is requesting jury trial and constructive trust be imposed over the joint venture. Date of trial is pending.

Posted by Industrial at 07:55 AM | Comments (0)

January 21, 2022

Products and Applications Proliferate in the Growing Market for Surgical Sealants, Glues and Wound Closure

Clinical experience with sealants, hemostatic agents, glues and a variety of novel wound closure technologies is coinciding with increased caseload in many different specialties including orthopedic, cardiovascular, dermal, surgical, neurology, and others. These multiple opportunities are driving an $11 billion market by 2014

(PRWEB) January 21, 2022 -- The market potential for products in the surgical securement field is driven by a combination of new technologies coming to market and expanding application caseloads. The potential for these products will grow steadily over the coming decade as surgical practices improve and the benefits of new products address the requirement for fast and effective closure.

MedMarket Diligence forecasts that approximately 70 million procedures around the world might benefit from sealants, glues, and other wound closure products in this group. Select products and applications will grow at rates near 20% annually.

In the next few years, we will see strong penetration of new therapies into new procedure areas, and some new introductory techniques for treatment of orthopedic, cardiovascular and neurological procedures, particularly in the second half of this decade, when several new products and procedures will appear in all of these categories.

A number of market leaders have consolidated their positions within the surgical closure and securement markets through successful internal development programs and through technology partnerships with innovative vendors of next generation technologies. For example, U.S. Surgical and Ethicon are major suppliers of cyanoacrylate products in the USA; with dominant sales resource to sell these products these companies lead the market, although they will face competition from the Canadian company Glustitch, the UK-based MedLogic and others. Synovis has targeted cardiovascular and other procedures, and has a range of closure products and has recently partnered with GEM to develop and exploit GEM’s internal high strength glue product (Glubran) in the USA.

The market remains replete with competitors, including Focal (Genzyme Biosurgery), Angiotech BioMaterials (Cohesion Technologies), Fusion Medical, Confluent Surgical, CryoLife, Medchem (C.R. Bard), Tissuemed, Surgical Sealants, Ethicon/Closure Medical, U.S. Surgical (Tyco Group), Haemacure, MedLogic Global (Advanced Medical Solutions), GEM srl, Chemence, Glustitch, Berlin Heart, and many others.

The "Worldwide Surgical Sealants, Glues and Wound Closure Market, 2004-2014" report, published January 2005, covers sealants, glues, tapes, sutures, staples, hemostats, fibrin sealants/glues, and medical adhesives. The report details the clinical and technology developments underlying growth and opportunity in the market, detailing products on the market and under development, with detail on market size and forecast, competitor market shares, competitor profiles and market opportunity. Details of the report, including table of contents and list of exhibits, are available at http://www.mediligence.com/rpt-s122.htm.

MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. The company publishes the “MedMarkets” newsletter, a monthly analysis of the market implications of new medical technology and dedicated reports on technology markets. For more information on MedMarket Diligence, LLC, contact Patrick Driscoll at (949) 859-3401, email (http://www.mediligence.com/contact_us.htm) or visit http://www.mediligence.com

Posted by Industrial at 07:50 AM | Comments (0)

January 20, 2022

Galvanon Signs Certified Premium VAR Agreement with ViewSonic

Galvanon’s eClipboard patient self-service check-in solution to feature wireless display from ViewSonic

Maitland, FL (PRWEB via PR Web Direct) January 20, 2022 -- Galvanon, the patient experience company, today announced it has signed a certified premium value-added reseller agreement with ViewSonic Corp., a worldwide visual display product leader. Under the terms of the agreement, the two companies will combine development resources to introduce Galvanon’s eClipboard automated patient registration and check-in utilizing ViewSonic’s V210 airSync® wireless display to the healthcare industry.

Galvanon helps healthcare organizations to enhance the patient experience through a variety of hardware and software solutions, including eClipboard and MediKiosk™, patient self-service kiosk solutions that automate patient registration and check-in processes. The ViewSonic wireless display will be sold as a part of eClipboard, Galvanon’s wireless kiosk solution.

“Galvanon’s self-service approach to patient registration and check-in opens a whole new market for our wireless displays,” said Dan Coffman, senior product manager at ViewSonic. “This potential of this opportunity is exciting because of the tremendous impact the resulting solutions can have for hospitals and physician practices.”

After patients check in electronically using eClipboard, front desk staff can also use the device to wirelessly monitor a patient’s treatment, status and location throughout the encounter as well as track workflow and check patient wait times.

“By combining our patient check-in software with ViewSonic’s wireless displays, our customers can eliminate redundant paperwork for patients, resulting in shorter wait times and increased patient satisfaction,” said Chakri Toleti, President of Galvanon. “This solution integrates with the healthcare organization’s existing systems for significant workflow improvements for the staff, including the elimination of much of the data entry and potential for errors associated with the check-in and registration processes.”

About Galvanon, Inc.
Galvanon helps healthcare organizations enhance the patient experience at home, in the hospital, and in the physician’s office through innovative solutions such as kiosks, Web self-service applications and technology that streamlines everyday patient interactions and improve patient flow through the healthcare process. For more information, visit www.galvanon.com/healthcare.

Press contact:
Cathi Hilpert
407-667-0669

Sales contact:
Gary Anthony
817-832-1060

Posted by Industrial at 07:47 AM | Comments (0)

Vitabase.com Launches New Website for Revitacil, a New Formula for Wrinkle Reduction and Stretch Mark Repair

Revitacil.com to Offer Revitacil, a Blemish Cream that Offers Effective Treatment for Wrinkle Reduction and Stretch Mark Repair

Loganville, GA (PRWEB) January 20, 2022 -- Vitabase.com announced the launch of their new website Revitacil.com, a website that distributes Vitabase.com’s new formula for stretch mark removal, wrinkle reduction, and blemish cream. Revitacil also helps improve the appearance of stretch marks, wrinkles and scars. Revitacil has assisted expecting mothers, weight lifters, and people with wrinkle reduction, stretch mark repair and scar removal.

Stretch marks occur because an area in the skin becomes deficient in collagen and elastin. Revitacil works to restore collagen and elastin to normal levels using two different kinds of ingredients - collagen fractions and herbal extract.

Collagen fractions are designed to increase the skin's thickness, which makes it easier for the skin to be nourished properly. As a result, it will look younger and healthier. The skin naturally gets thinner as aging occurs, and collagen fractions can help combat this problem.

Revitacil stimulates collagen production, and also improves elasticity, normalize scars and wrinkles, and reduce inflammation. Revitacil’s effectiveness stems from the use of four key herbal substances. Emblica is a powerful antioxidant extract which has been shown to increase skin hydration and skin lipids. Siegesbeckia Orientalis Extract has been in use for thousands of years as a skin inflammation soothing agent as well as a wound healing balm. Biopeptide-CL is a synthetic protein which makes collagen more lipophillic and more compatible with the human skin. Palmitoyl Tetrapepdtide-3 is a synthetic peptide that has been shown to make a substantial difference in the appearance of stretch marks. In one study, 93% of the subjects who participated showed a marked improvement in the length and depth of stretch marks and wrinkles.

No topical cream can completely eliminate all skin damage but the ingredients in Revitacil work together to support the health of the skin, wrinkle reduction and stretch mark repair.

About Vitabase.com
Vitabase.com provides its customers with quality health supplements at reasonable prices and offers them exceptional, personal customer service. Vitabase.com is built on the principle that if it provides its customers with honest information, they will trust Vitabase.com with their health. Vitabase’s brand supplements are made exclusively for the company and are scientifically backed products Vitabase.com also offers other popular health supplements ranging from vitamins and herbs to skin care enhancers.

Revitacil is available at www.revitacil.com

Posted by Industrial at 07:46 AM | Comments (0)

World's First Contoured Electric Heating Pad Solves Problems Caused By Old Flat Pads

No longer a need to use duct tape to secure the old flat heating pad to your shoulder, elbow or knee. New, curved heating pad is a hit.

(PRWEB) January 20, 2022 -- Jan Halderman of Memphis had not slept well in years. The pain from the bursitis in both her knees had kept her awake. That is, until she discovered a new product, the first 'non-flat' electric heating pad, made especially for the shoulders, elbows and knees – which is called JointHeat.

The inventor, Daniel Lewis of Jacksonville, FL, said his father had been suffering with an arthritic shoulder for several weeks. He had watched him use duct tape in attempts to 'fix' the flat heating pads to the round shape of his shoulder.

He did a bit of research and found that heat was indeed a major factor in the healing process of most all body ailments – especially joint pain. Heat causes the blood vessels to expand, which allows more blood to the affected area, which delivers greater numbers of white corpuscles and other healing elements. The medical term for that describes this process is 'vasodilation'.

He learned it was necessary to apply constant, steady heat to the ‘entire’ joint – whether it was the shoulder, the elbow or the knee – for extended period of times in order to receive the benefits of the heat. However, it was obvious to him that it is not possible to get a flat electric pad to envelop one of these curved joints. Therefore, they allow much of the heat to escape.

Lewis claims JointHeat ‘silhouettes’ these three joints and traps as much as 90% of the heat, which allow the user to use the device on the low heat setting for a longer period of time.

Dr. Mary Soha, a pediatrician who practices pediatric sports medicine in Jacksonville agrees, she said “You can conform it to many joints – shoulder, knee, elbow – and get a more even heat dispersal for the area.”

Soha’s patient have been using the device for six months and find it more comfortable than standard heating pads.

The first ‘in-store’ market test at a Walgreens store in Memphis was a phenomenal success. The entire inventory was sold out within an hour. They then sold out the restocked shelves within 30 minutes. Disappointed buyers filled up three pages with their names and phone numbers, asking to be contacted as soon as a new shipment was delivered.

Because of its instant popularity, a web site was established so that anyone can simply click on www.jointheat.com to order this innovative new product, the “World’s First Contoured Electric Heating Pad”. According to Lewis, an additional benefit is that in buying directly from the manufacturer, you can purchase JointHeat for $29.99, a savings of 40% off the suggested retail price of $49.99. - William Parrish, GMI Publishing.

Posted by Industrial at 07:41 AM | Comments (0)

WFNN Recommends Meridian Medical

Company Shows Bright Future for Earnings Growth by Helping People in Alternative Medicine
Dr. Joseph de Beauchamp of World Financial News Network started coverage and gives favorable analysis to Meridian Medical as a company shows bright future for earnings growth by helping people in alternative medicine.

Seattle, WA (PRWEB) January 20, 2022 -- WFNN's consistently outperforms established industry benchmark indicators. Based on in-depth research and analysis, their analysts recommend securities worldwide showing the highest probability for stock price appreciation. With constant vigil, WFNN looks for economic opportunities in the private and public company sectors.

Dr. Joseph de Beauchamp, WFNN's Chief Independent Analyst, said, “Throughout the world, the medical environment is changing. In Korea, for example, the popularity of Oriental medicine is rising rapidly. The importance of alternative medicine has been acknowledged in Europe, North America and in Asia, and accordingly, these markets have been expanding. As a result, the interest in Oriental medicine is growing worldwide with the demand for Oriental medical instruments increasing. Therefore, as an Oriental medical instruments manufacturer, the Meridian is well positioned in an expanding market. This company shows dynamic growth since the sector continues to show increases in all categories of revenue and capital. WFNN sees the stock moving up to $2.00 per share in the next twelve months and hitting one cent in earnings for the period."

For brief information of this new, dynamic company, examine: http://wfnn.info displaying in the search engine section.

About WFNN: World Financial News Network provides a unique blend of data, timely information and today's technologies to assist with up-to-the-minute investment and economic values on markets and investments around the world.

About Meridian Medical:
The Meridian is engaged in the research, development, manufacturing and sales of medical devices for the Natural/Alternative Medicine industries. The Meridian's major customers are Oriental medical hospitals and clinics as well as Western medical hospitals and clinics. The Meridian is currently selling its products in Korea, China, Latin America, and North America and to the Association of South East Asian Nations (ASEAN). The Meridian intends to continuously expand its sales efforts in several countries through establishment of additional branch offices, distributors, and sales agencies. The Meridian has sales agencies in Daegu, Daejeon, Pusan, and Gwangju in Korea and in California, U.S.A.

Contact:
Debbie Williams
Ann Brazier
Meridian Medical
2150 w. Broadway, Suite 306
Vancouver, British Columbia
Canada V6K4LN
877-738-8119
604-738-8119
http://www.meridianmedical.ca

Posted by Industrial at 07:38 AM | Comments (0)

Mountain Park Health Center (MPHC) Subscribes to Saferating’s Technology for Patient Safety and Cost Containment

Saferating Inc. announces that Phoenix-based Mountain Park Health Center has purchased a suite of medical reporting tools utilizing the power of Paperless Form Technology (PFT) for its four sites. MPHC will utilize Saferating.com to report, manage, and analyze the quality and risk management systems in all four clinics.

Lewiston, Maine (PRWEB) January 20, 2022 – In November 2004, staff gained instant web access for secure reporting of medication errors, adverse drug reactions, pharmacist clinical interventions and system-wide incident reporting. Mountain Park Health Center began utilizing Saferating’s Paperless Form Technology (PFT) in its four Phoenix area health centers. Risk, Quality, and Pharmacy leadership are now notified instantly via Saferating’s automated email function upon submission by staff and have real time access to all data reported. Follow-up and analysis utilizes Saferating’s powerful query engine and report generator to enhance its system improvement and contribute to compliance with HIPAA and JCAHO standards.

Because the Saferating reporting systems are paperless and available 24/7/365, it is expected the system will save extensive labor hours and the associated costs. Mountain Park Health Centers is proud to take this step to enhance patient safety, save staff time, and contain costs. Learn more at Saferating.com

About Saferating Inc
A leader in Paperless Form Technology solutions for the healthcare industry, Saferating.com provides HIPAA compliant applications to document and report clinical activity. Saferating has developed other solutions for meeting JCAHO requirements for reporting of Adverse Drug Reaction, Medication Errors, Anticoagulation Medication Tracking, Incident Reporting, Patient Satisfaction Surveys, and Competency Assessment. SAFERATING.COM’s solutions improve patient care, reduce costs by eliminated paper-based forms, and eliminated redundant data entry. Saferating.com is based in Lewiston Maine. For more information on Saferating.com, please visit www.Saferating.com

About Mountain Park Health Center
Mountain Park Health Center operates four clinics in the metro Phoenix area which treat Medicare patients, privately insured, and uninsured patients. MPHC participates in Arizona Health Care Cost Containment System (AHCCCS) and in the Arizona tobacco tax primary care programs. Referral systems into secondary and tertiary care have established the health center as a leader for both physical and mental health. MPHC provides a vast array of services that are based upon the individual needs of the communities they serve.

Posted by Industrial at 07:35 AM | Comments (0)

Kawasumi America Recieves Medical Device License from Health Canada to Market Medical Disposables

Kawasumi Laboratories America, Inc. announced today the receipt of Class II medical device licenses from Health Canada, enabling the company to commercially sell and distribute their Kawasumi branded oncology, hematology and hemodialysis products in the Canadian marketplace.

Tampa, FL (PRWEB) January 20, 2022 -- Kawasumi Laboratories America, Inc. has announced the receipt of Class II medical device licenses from Health Canada, enabling the company to commercially sell and distribute their Kawasumi branded oncology, hematology and hemodialysis products in the Canadian marketplace.

"Kawasumi is pleased to receive this medical device licensure from Health Canada as it supports our strategic direction for expanding our sales and market coverage. This demonstrates that we are truly growing our global company," said Ron Lamb, president of Kawasumi Laboratories America.

Scott Horowitz, marketing manager for Kawasumi added, "we’re excited to offer the Canadian market the same safety products we currently offer in the U.S., which include non-DEHP gravity I.V. sets and our newest K-Shield™ needle safety technology. Just as in the U.S. market, patient safety has become a such a growing concern that Canadian health care facilities and clinicians are now looking for safer IV sets and needle stick prevention alternatives."

Kawasumi’s products are manufactured in accordance with ISO 13485:1996 and the company’s quality systems have been certified by TUV America. Kawasumi’s Class II medical device licenses will cover a portfolio of products including the following:

Non-DEHP Gravity I.V. Administration Sets (License #66630)
Non-DEHP sets are for both fluid administration of chemotherapy and routine infusion applications. Key pharmaceutical applications include Taxol, Taxotere, Remicade and Erbitux. Gravity IV sets are available in both needleless access and standard injection sites as well as filtered (.22 micron) and non filtered sets.

Port Access Infusion Sets (License #66633)
Port access infusion sets are used for accessing patients that have surgically implanted subcutaneous ports. Port access infusion sets have a non-DEHP fluid path and the needle hub and wing design offers secure and accurate needle placement. As an added measure of safety, a K-Shield needle safety accessory device is available.

K-Shield Winged Blood Collection Sets and Small Vein Infusion Sets (License #66631 & #66634)
Blood collection sets ("butterflies") with multiple sample luer adapter and small vein infusion sets are available in both K-Shield safety and non-safety versions. K-Shield provides a safe collection environment for both clinician and patient. The fast and easy to use integrated K-Shield safety device reduces accidental needle sticks. Equally important, the needle point is immediately covered upon removal from venipuncture site, ensuring a clinician’s confidence in safety.

Blood Drawing Kits and Phlebotomy Sets (License #66629 & #66635)
Since Kawasumi’s 600 mL blood drawing kits do not contain unnecessary anticoagulant solution, it makes an economical choice for therapeutic phlebotomy applications. Additional features include a pre-attached 16G venipuncture needle with backeye to optimize blood flow, sample port, and pinch clamp for easy prevention of backflow. Kawasumi also has available two types of low-cost phlebotomy sets with pre-attached needles for accessing all vacuum bottles.

Arterial Venous Fistula Sets (License #66632)
For hemodialysis applications, Kawasumi will be offering a complete line of ultra thin walled and silicon coated arterial venous fistula needles which reduces patient discomfort and minimizes tissue damage at the puncture site. Additional attributes consist of textured finger grips that improve grip during placement and pliable, extremely elastic tubing that resists kinking when bent. The fistula sets come in a variety of needle gauges and lengths as well as with either fixed wing without backeye, fixed wing with backeye or rotatable hub with backeye.

Kawasumi is actively seeking top distributors located in Canada to carry some or all of the Kawasumi brand product line.

For more information on Kawasumi America’s complete line of oncology, hematology and hemodialysis products, or how to become a distributor, call 1-800-KAWASUMI (529-2786) or visit www.kawasumiamerica.com.About Kawasumi

Founded in 1954, Kawasumi Laboratories, Inc. is a leading manufacturer of medical devices and pharmaceuticals. Headquartered in Tokyo, Japan, the company is listed on the Second Section of the Tokyo Stock Exchange. Kawasumi Laboratories America, Inc., based in Tampa, Fla. since 1991, is a wholly owned subsidiary of Kawasumi Laboratories, Inc.

Posted by Industrial at 07:31 AM | Comments (0)

January 19, 2022

Healthcare Group Purchasing Organizations (GPOs) Poll Results Released

Nationwide poll highlights expected GPO power notwithstanding Senate investigation or NY Times investigative articles.

Mechanicsburg, PA (PRWEB via PR Web Direct) January 19, 2022 –- Healthcare Group Purchasing Organizations (GPOs) will not only survive, but will thrive. That, according to a recently conducted nationwide poll, is the expectation of hospitals and suppliers. The positive outlook comes despite ongoing Senate investigations into GPO practices that has led to the Medical Device Competition Act of 2004 (S. 2880), as introduced by Senators Mike DeWine (R-OH) and Herb Kohl (D-WI), chairman and ranking member, respectively, of the U.S. Senate Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights.

How well will GPOs partner over the next few years to suppliers and its membership? And which GPO is currently the best partner? Those are just some of the answers that StratCenter.com’s "Voice Your Opinion!" ("VYO!") Poll determined. This "VYO!" was submitted to the entire readership of StratCenter.com’s Supply Chain Strategies e-Newsletter during December 2004.

StratCenter.com is releasing its complete results and is making its analysis and presentation available at no cost to qualified business-of-healthcare executives via its website at: http://www.StratCenter.com/go/?11122.

"This "VYO!" provides an important understanding into how the market views the role of GPOs," says Patrick Michael Plummer, Founder & CEO of StratCenter.com. "The poll was broken down into three parts: Part I reports on GPO partnerships with its members (hospitals, IDNs, non-acute care, etc.); Part II reports on GPO supplier partnerships; and Part III answers the following question: 'If you could partner with only one GPO, which one would you choose?'" This poll was conducted of StratCenter.com's Supply Chain Strategies (SCS) e-newsletter readership in December 2004.

The industry expects that GPOs are responding much more aggressively to meet its members' needs, including the IDNs. Important to these results, members are acknowledging GPOs to be a valuable business partner, and are committing more allegiance to the GPOs in return. Novation came in tops overall for being the best partner to its members.

Overall, the market perception is that relationships between GPOs and suppliers will generally stay about the same as today, with just slightly more respondents believing it will deteriorate more than it will improve. Like the best partner to its membership, Novation also came in tops.

Still, there remain significant concerns that the Senate investigation into healthcare group purchasing, along with the potential passage of the Medical Device Competition Act, poses a grave threat to GPOs.

This "VYO!" poll reports on the seven (7) national GPOs in the United States, including Amerinet, Broadlane, Consorta, HealthTrust Purchasing Group, MedAssets, Novation, and Premier.

About StratCenter.com
StratCenter.com is an Intelligent Online Service providing hospital, IDN, and GPO databases and news for the healthcare supply chain.

Posted by Industrial at 07:29 AM | Comments (0)

Tooth Whitening Product Innovations: Texas Dental Firm Offers Novel Tooth Whitening Product Line

Ultra-White Products, Inc., a tooth whitening product manufacturer in Texas, now offers an attractive alternative to marginally effective over-the-counter tooth whitening product lines and costly dental treatments. The company’s novel tooth whitening product affords users the ability to obtain custom application trays and whitening gels at a fraction of the cost normally associated with professional cosmetic dentistry and are far more effective than over-the-counter solutions. The company has a worldwide following with over 30,000 clients and is owned an managed by a practicing dentist.

Plano, TX (PRWEB) January 19, 2022 - Consumers frustrated by marginal results and the discomfort caused by the one-size-its-all tooth whitening gel application trays provided with over-the-counter tooth whitening products, may want to consider taking advantage of a unique tooth whitening product line offered by Ultra-White.com, a Plano, Texas dental lab. The company currently has over 30,000 satisfied clients.

“Traditionally, consumers have had but two choices when it comes to brightening their smiles,” says Tim Huckabee, the company’s founder and a practicing cosmetic dentist. “They could see a cosmetic dentist like myself who charges upwards of $500 to make a custom application tray and then pay an addition $200 or $300 for on-going treatment, or they could take advantage of any number of over-the-counter solutions, the vast majority of which produce marginal results.”

Ultra-White.com, his company’s internet portal, offers consumers an affordable and effective alternative. “When a consumer orders our tooth whitening system, they receive all the materials they need to make the same molds we fabricate in our lab on behalf of our local clients. Once made, molds are returned to our dental lab where a custom application is made right next to the one’s we are charging our client’s $500 to make and at considerably less cost,” Huckabee says.

A tooth tray is necessary to hold the whitening gel against the user’s teeth. According to Huckabee, custom fit trays are not only decidedly more comfortable, they are far more efficient. “One-size-fits-all applications are not only uncomfortable, they are pretty much hit and miss,” he says. “A custom made tray can be worn without discomfort and for an extended period of time. In addition, custom trays are more efficient because less gel is needed and they whiten teeth much faster.”

The company’s offering is not limited to custom trays. It offers a tooth whitening gel that is probably the biggest reason the company continues to prosper. “Ultra-White 16% and 22% gel solutions use carbamide peroxide as the whitening agent. When used, the carbamide peroxide breaks down to hydrogen peroxide which is what ultimately whitens the teeth,” he says.

The company offers two solutions. “Individuals with sensitive teeth prefer our 16% gel. While whitening more gradually, it causes less tooth sensitivity. The 22% gel whitens quickly but can cause a temporary sensitivity to extremes in temperature. Used on a daily basis, the 16% gel has to be applied for two weeks to achieve maximum whiteness,” Huckabee says. Normally, the 22% gels normally takes about 10 days.”

The company which has been offering its tooth whitening product on-line for five years, has an enviable reputation in the industry and was recently awarded Yahoo’s Five Star rating for customer satisfaction. The reason is simple enough. The company stands behind its products. “If during or after using our products a client isn’t satisfied with her or his results, he/she can return the kit and get an instant refund,” Huckabee says.

Since the company went on-line in 1999, less than 2% of the company’s customers have requested a refund. Huckabee is very proud of that. “Not only are our clients satisfied with our tooth whitening product line, they routinely recommend our products and services to others and that’s a source of great personal satisfaction,” he says.

Ultra-White Products, Inc. is located in Plano, Texas. Dr. Huckabee can be reached via the company’s web site, by phone at (800)460-3081 or via the email hyperlink located in the right hand column.

Ron Scott
Fast Track SEOP
Riverside, CA 92507
(951) 784-2274

Global Distribution: Tooth Whitening Product and Tooth Whitening Gel

Posted by Industrial at 07:26 AM | Comments (0)

Denver PR Consultancy, Absolutely Public Relations, Announces Its Third Contract Agreement with Baxa

As of January 1, 2005, Absolutely PR embarked on its third contract with Baxa Corporation for media relations services. In 2004, Baxa Corporation’s media relations campaign yielded 50 trade press placements; approximately 4.16 per month on the average. Publications covering Baxa Corporation last year included: Denver Business Journal, Rocky Mountain News, Pharmacy Practice News, Drug Topics, For The Record, U.S. Pharmacist, Health Management Technology, Hematology Oncology News & Issues, Nursing Management, Houston Business Journal, The Manufacturer Magazine, Journal of Infusion Nursing, Pharmacy Purchasing & Products, Pharmacy Times, Packaging News (UK) and The Medical Post.

Lakewood, CO (PRWEB) January 19, 2022 -- Denver public relations resource, Absolutely Public Relations, will again provide media relations consulting services to Englewood-based Baxa Corporation. The announcement is made by Absolutely PR owner, Maggie Chamberlin Holben, APR, who says this is the third contract her consultancy has engaged in with Baxa since 2003.

"Baxa Corporation's media relations campaign has yielded an ad value equivalency exceeding $116,000 and a circulation exposure of 3.2 million thus far. We've been able to keep up the momentum of an ongoing media relations campaign and, certainly in 2004, have seen the very positive results of the consistent ongoing activity," Holben says.

Since Absolutely PR’s first contract with Baxa Corporation in 2003, exposure has occurred in the following publications:

Denver Business Journal (four placements)
Rocky Mountain News (three placements)
Managing Infection Control
RN Magazine
Pharmacy Practice News (five placements)
ComputerWorld
Drug Topics (four placements)
For The Record (two placements)
U.S. Pharmacist
Health Management Technology
Hematology Oncology News & Issues
Nursing Management
Houston Business Journal
The Manufacturer Magazine
Journal of Infusion Nursing
Pharmacy Purchasing & Products (three placements)
Pharmacy Times (two placements)
Packaging News (UK)
The Medical Post

In addition to the ongoing news release program, Absolutely PR has also posted two experts on behalf of Baxa Corporation (James Jorgenson, RPh, MS, and Martha Polovich, MN, RN, AOCN) on its "Expert Information For Journalists" website at http://www.expert411.com/_wsn/page9.html covering the safe handling of hazardous drugs. Baxa distributes the innovative PhaSeal® closed system for the safe handling of hazardous medications. In 2005, additional postings are anticipated at either www.expert411.com or Absolutely PR’s national newsroom (http://www.PublicRelationsNewsroom.com) on behalf of Baxa Corporation.

Absolutely Public Relations has been in business since April 1999 and specializes in media relations. Media relations is a combination of strategy and tactics that yield impactful editorial media placements. Holben is accredited by the Public Relations Society of America and is also a member of the organization’s Counselors Academy. The ideal client for Absolutely PR is one that needs three to ten hours per week of media relations consulting services and can sustain at least a six-month campaign, preferably 12 months, with plenty of news hooks for the media.

Your can learn more about news hooks at the website: http://www.absolutelypr.com.
Holben also offers these other websites to help her clients achieve media exposure:

http://www.PublicRelationsNewsroom.com
http://www.Exper411.com
http://www.DenverPRNewsroom.com
http://www.Online-Presskit.com

Results for several Absolutely PR campaigns are posted as PDF attachments to this news release for those readers curious about what to expect from a media relations program. Links are found at the column to the right detailing the following media relations campaigns:

Trade Media Campaign – New Product Environmental Remediation
Bylined Article Campaign for New Pricing Model – Military Trade Press
Denver Media Campaign – Key Executive Announcement
National/Trade/Local Campaign – 25th Anniversary in Business
Trade & Local Campaign – Community Issue Awareness
National Awareness Campaign – Innovative Contact Lens Product
National Awareness Campaign – New Product for Pain Management
Denver Media Campaign – National Expansion Into Denver Market
Trade Media Campaign – Medical Device Company

Holben recently announced that Absolutely Public Relations achieved numerous national, trade and local editorial placements in 2004. Results were recapped in a "yearend review" news release:
http://www.prweb.com/releases/2004/12/prweb192321.php

First quarter, a national placement occurred in the Discover Financial Services “Inside Biz” newsletter that circulates to 1.3 million recipients:
http://www.prweb.com/prfiles/2004/12/28/192321/DiscoverCardInsideBizfinal.pdf

Also first quarter, Absolutely PR’s contact lens client was featured on a segment for the E! Style Network, reaching some 33 million subscribers:
http://www.prweb.com/prfiles/2004/12/28/192321/APRNewsReleaseAICTonStyle.pdf

Holben was interviewed about crisis management on 850 KOA Radio for the morning drive segment:
http://www.prweb.com/prfiles/2004/12/28/192321/APRNewsReleaseKOAInterview.pdf

National placements were also achieved in Inc. Magazine:
http://www.prweb.com/releases/2003/12/prweb92273.php

Washington Times:
http://www.prweb.com/prfiles/2004/12/28/192321/ClippingDailyNewspaperDCMarket08January2004.pdf

And, Woman’s World during the year:
http://www.prweb.com/prfiles/2004/12/28/192321/ClippingNationalPlacementConsumerWomensMagApril2004.pdf

Further, a Fortune 500 company using Absolutely PR services for Denver localization in 2004 achieved six placements with its Metro Denver announcement exceeding 1.4 million in circulation reach and $16,000 in ad value equivalency.

For more information about Denver PR resource Absolutely Public Relations, go to http://www.absolutelypr.com. For further information about Maggie Chamberlin Holben go to http://www.maggieholben.com. Call Holben's office at 303-984-9801 or e-mail e-mail protected from spam bots.

# # #

About Baxa Corporation:
As a leading provider of devices and systems for the preparation, handling, packaging, and administration of liquid medications, Baxa manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Headquartered in Englewood, Colorado, Baxa has subsidiaries and sales offices in Canada, the United Kingdom, Germany and Denmark; and distribution partners worldwide. Further information is available at http://www.baxa.com

Posted by Industrial at 07:22 AM | Comments (0)

Soothing Pain Relief Product - Nasa's Spinoff Magazine Features Unique Heating Pad Invention

An amazing invention, the ThermiPaq(TM), a heating and cooling pad that utilizes a clay based, thermal ceramic compound to provide reusable and soothing pain relief, has been featured in NASA's most recent "Spinoff 2004" magazine which details the steps taken to discover this remarkable heating/cooling pad and the influence NASA provided in the discovery.

Springfield, IL (PRWEB) January 19, 2022 -- While employed at NASA as a systems engineer, Tom Hughes gained valuable knowledge and expertise in microwave technology as well as packaging materials. This experience led to the development of Hughes' amazing invention, ThermiPaq(TM), a heating and cooling pad that utilizes a clay based, thermal ceramic compound to provide reusable and soothing pain relief.

Hughes patented the material as Thermal Ceramix(TM) and teamed up with four partners to form Thermionics Corporation, now based in Springfield, IL.

In NASA's most recent "Spinoff 2004" magazine, Hughes, Thermionics Corporation, and ThermiPaq(TM) are featured, detailing the steps taken to discover this remarkable heating/cooling pad and the influence NASA provided in the discovery.

The article details the superior qualities and characteristics of the ThermiPaq(TM) products which set them apart from their competitors. Radiant energy, produced by the ceramic materials produces a deep, penetrating relief from pain and discomfort.

ThermiPaq(TM) has been proven highly effective in the relief of pain caused by arthritis, sports injuries, sinus/stress headaches, joint stiffness, and chronic back pain.

The technology utilized to create the clay based materials unique to ThermiPaq(TM) products produces superior, high quality
characteristics:

- Environmentally safe
- Re-usable
- Heat/cold lasts longer than gel/liquid-based products
- Temperature levels can be adjusted according to the
patient's needs
- Cools in the freezer and heats in the microwave
- Maintains its flexibility at freezer temperatures
- Even product distribution - no "saddlebagging"
- Even temperature distribution - no "hot spots"

To read the NASA Spinoff 2004 magazine article or to learn more about ThermiPaq(TM) and other Thermal Ceramix products, please visit the followng web address: http://www.thermipaq.com/news_testimonials.html

For an interview or more information, contact Gregg Harwood at 3501 S. 6th St., Springfield, IL 62703, or by phone at 217-529-4280

Posted by Industrial at 07:19 AM | Comments (0)

January 18, 2022

New Generation Thermometer Increases Comfort and Accuracy

Auto Control Medical, a Canadian distributor of home health care products, introduces the latest innovation in thermometry, the MyHealth™ dual-mode TempleTemp® Thermometer.

Montreal, Quebec (PRWEB) January 18, 2022 -- The MyHealth™ TempleTemp® Thermometer, a truly "touchless" thermometer is finally available to Canadians! This unique dual-mode thermometer utilizes infrared and ambient temperature compensation technology to scan for accurate and fast temperature of the temple, liquids, objects, ambient air etc.

The MyHealth™ TempleTemp can be used on people of all ages and is faster, safer and easier to use than ear thermometers and traditional digital and glass-mercury themometers. For more accurate readings, while gently scanning the temple, the thermometer must be kept at a distance of no more than 0.5 cm without touching the skin. When taking the temperature of liquids, objects or ambient air, the thermometer can scan once for one temperature
reading or continuously for continuous readings. Results are displayed on its large LCD screen.

Temperatures can be measured in both Celsius and Fahrenheit. TempleTemp offers the ability to store up to 25 temperature readings in its memory and is truly non-invasive. Measurements can even be taken while the young child is sleeping, to test the temperature of its bath water, its bottle or its food. Older people with little or no feeling in their extremities can also benefit from TempleTemp by measuring their coffee or tea, food and bath or shower water to avoid getting burnt.

The MyHealth Dual-Mode TempleTemp provides:

- Readings in Celcius and Fahrenheit
- Fast, accurate readings in seconds
- Fever alarm warning
- Storage of up to 25 readings in memory (temple readings only)
- Automatic power off
- 3V lithium battery and wrist strap included
- One-year warranty

Due to its unique shape and size, the TempleTemp allows for easy portability and can fit into just about any purse or bag.

The MyHealth Dual-Mode Infrared TempleTemp Thermometer is distributed in Canada by Auto Control Medical, a leading Canadian distributor of home health care products. The TempleTemp is the latest addition to Auto Control Medical's product line. More information about the MyHealth TempleTemp is available at www.autocontrol.com

Posted by newsupdate at 06:48 AM | Comments (0)